Related Experiment Video

Updated: Aug 26, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Novel pituitary ligands: peroxisome proliferator activating receptor-gamma

Anthony P Heaney1

  • 1Division of Endocrinology, Cedars-Sinai Research Institute, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA. heaneya@cshs.org

Pituitary
|February 20, 2004
PubMed

Insights

PPAR-gamma activators, like thiazolidinediones, show promise for treating pituitary tumors. These drugs inhibit tumor growth and hormone secretion, offering a potential new oral therapy.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Pituitary tumors cause significant health issues, often lacking effective drug treatments.
  • Current management relies primarily on surgical intervention.
  • Nuclear hormone receptor PPAR-gamma is highly expressed in various human pituitary tumors.

Purpose of the Study:

  • To investigate the therapeutic potential of PPAR-gamma activators in pituitary tumors.
  • To evaluate the effects of thiazolidinediones on pituitary tumor cell growth and hormone secretion.

Main Methods:

  • Assessed the impact of PPAR-gamma activators on human and murine pituitary tumor cell lines in vitro.
  • Administered rosiglitazone to mice with induced pituitary tumors to evaluate in vivo effects.
  • Measured hormone levels (ACTH, corticosterone, GH, PRL, LH) in treated animals.

Main Results:

  • PPAR-gamma activators induced cell-cycle arrest and apoptosis in pituitary tumor cells.
  • In vitro and in vivo tumor growth was significantly suppressed by rosiglitazone treatment.
  • Hormone secretion and levels (ACTH, corticosterone, GH, PRL, LH) were attenuated in treated animals.

Conclusions:

  • PPAR-gamma is a viable molecular target for pituitary adenoma therapy.
  • Thiazolidinediones demonstrate efficacy in inhibiting pituitary tumor growth and hormone hypersecretion.
  • PPAR-gamma ligands represent a potential novel oral medical management strategy for pituitary tumors.

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...